A RELATIVE BIOAVAILABILITY STUDY OF THE GRAZOPREVIR/ELBASVIR FIXED-DOSE COMBINATION IN HEALTHY SUBJECTS

被引：0
|
作者：
Davit, B. M. [1 ]
Alon, A. [1 ]
Caro, L. [2 ]
Feng, H. [2 ]
Guo, Z. [2 ]
Kesisoglou, F. [2 ]
机构：
[1] Merck Res Labs, Rahway, NJ USA
[2] Merck Res Labs, N Wales, PA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-137
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [1] GRAZOPREVIR/ELBASVIR FIXED-DOSE COMBINATION FOR HEPATITIS C
    Gamal, N.
    Andreone, P.
    DRUGS OF TODAY, 2016, 52 (07) : 377 - 385
  • [2] Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects
    Milan-Segovia, R. C.
    Vigna-Perez, M.
    Romero-Mendez, M. C.
    Medellin-Garibay, S. E.
    Vargas-Morales, J. M.
    Magana-Aquino, M.
    Romano-Moreno, S.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (01) : 49 - 54
  • [3] A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
    Li, Haiyan
    Yang, Zhenhua
    Zhang, Shuang
    Xu, Lin
    Wei, Yudong
    Jiang, Jun
    Caro, Luzelena
    Feng, Hwa-Ping
    McCrea, Jacqueline B.
    Li, Meng
    Xie, Shuang
    Wang, Jiangdian
    Zhao, Xu Min
    Mu, Shengmei
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2020, 12 : 1 - 11
  • [4] The relative bioavailability of 2 prototype fixed-dose combination formulations for amlodipine and rosuvastatin in healthy white and Chinese subjects
    Nwe, Htar H.
    Bullman, Jonathan N.
    Joshi, Shashidhar M.
    Stylianou, Annie
    Kapsi, Shiva G.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (02): : 131 - 140
  • [5] A STUDY ON THE RELATIVE BIOAVAILABILITY OF FIXED-DOSE ETHAMBUTOL-ISONIAZID COMBINATION
    QUIJANO, RF
    MARAMBA, NC
    MACARAEG, PVJ
    PHILIPPINE JOURNAL OF INTERNAL MEDICINE, 1984, 22 (03): : 117 - 122
  • [6] Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection
    Pijnenburg, Danielle W. M.
    van Seyen, Minou
    Abbink, Evertine J.
    Colbers, Angela
    Drenth, Joost P. H.
    Burger, David M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2661 - 2665
  • [7] A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects
    Okour, Malek
    Puri, Adeep
    Chen, Geng
    Port, Kathleen
    Berni, Alessandro
    Khindri, Sanjeev
    Schneider, Ian
    Tenero, David
    CLINICAL THERAPEUTICS, 2019, 41 (06) : 1110 - 1127
  • [8] PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OF FIXED-DOSE COMBINATION OF CLOPIDOGREL AND ASPIRIN VERSUS CO-ADMINISTRATION OF INDIVIDUAL FORMULATIONS IN HEALTHY SUBJECTS
    Choi, H.
    Ghim, J.
    Oh, M.
    Shon, J.
    Park, S.
    Seo, J.
    Shin, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S37 - S37
  • [9] Effects of a high fat meal on the bioavailability of the fixed-dose combination of amodiaquine and artesunate (ASAQ) in healthy subjects
    Barre, Jerome
    Lesauvage, Eric
    Thang, Carole
    Charron, Brigitte
    Lameyre, Valerie
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 77 (05): : 205 - 205
  • [10] Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation
    Milan-Segovia, R. C.
    Dominguez-Ramirez, A. M.
    Jung-Cook, H.
    Magana-Aquino, M.
    Romero-Mendez, M. C.
    Medellin-Garibay, S. E.
    Vigna-Perez, M.
    Romano-Moreno, S.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (11) : 1454 - 1460
12345